Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainM.D. Anderson Cancer Center / Merck Sharp & Dohme Corp. / National Cancer Institute (NCI)
ClinicalTrials.gov Identifier: NCT03873818
Investigators at M. D. Anderson Cancer Center have opened a Phase II clinical trial to study the side effects and how well low-dose ipilimumab (YERVOY®, Bristol‑Myers Squibb) works in combination with pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme) in treating patients with melanoma that has spread to the brain.
See additional details, including study location(s), eligibility criteria, contact information, and study results (when available) at ClinicalTrials.gov.
Send email to firstname.lastname@example.org for information about submitting qualified clinical trials for sponsored posts on this blog.
The information on my blog is not intended as a substitute for medical professional help or advice but is to be used only as an aid in understanding current medical knowledge. A physician should always be consulted for any health problem or medical condition.